Affomix Corporation
Harnessing advanced technology for swift, automated selection of human monoclonal antibodies for precise protein measurement in biological samples.
Harnessing advanced technology for swift, automated selection of human monoclonal antibodies for precise protein measurement in biological samples.
Affomix Corporation, founded in 2006, specializes in leveraging advanced technology for the swift, automated selection of human monoclonal antibodies. The company's mission is to bring proprietary mAbs, mAb microarrays, and mAb libraries to the market for various applications in research, drug discovery, diagnostics, and therapeutics within the Biotechnology and Health Care industries. Affomix focuses on the precise and sensitive measurement of extensive numbers of proteins in biological samples using their mAbs. The company received a notable $7.00M Series A investment on 22 February 2008 from a group of investors including Connecticut Innovations, Elm Street Ventures, and Four Seasons Ventures. With their commitment to cutting-edge technology and applications in the biotechnology and healthcare sectors, Affomix Corporation presents an intriguing opportunity for venture capitalists looking to invest in innovative solutions for protein measurement and antibody-based technologies.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $7.00M | 3 |
|
22 Feb 2008 |
No recent news or press coverage available for Affomix Corporation.
We care about your data, and we'd love to use cookies make your experience better.
